Game da-ciwon daji / jiyya / gwaji-na asibiti / cuta / tsuliya-ciwon daji / magani
Jiyya Gwajin gwaji na Ciwon Cutar Cancer
Gwajin gwaji shine karatun bincike wanda ya shafi mutane. Gwajin gwaji a wannan jerin sune don maganin cutar sankara. Duk gwaji akan jerin suna samun tallafi daga NCI.
Babban bayanin NCI game da gwajin asibiti yayi bayanin nau'ikan da matakan gwajin da yadda ake aiwatar dasu. Gwajin gwaji na duba sabbin hanyoyin kariya, ganowa, ko magance cuta. Kuna so kuyi tunani game da shiga cikin gwajin gwaji. Yi magana da likitanka don taimako yayin yanke shawara idan ɗaya ya dace maka.
Gwaji 1-23 na 23
Nivolumab bayan Haɗaɗɗiyar Tsarin Tsarin Lafiya don Kula da Marasa Lafiya tare da Babban Hadarin Mataki na II-IIIB Ciwon Cancer
Wannan rukunin gwaji na asibiti na biyu wanda aka bazu yayi nazarin yadda kyau nivolumab bayan haɗuwa da tsarin daidaitawa ke aiki don kula da marasa lafiya da babban haɗarin ciwon sankara na II-IIIB. Immunotherapy tare da kwayoyin cuta na monoclonal, kamar nivolumab, na iya taimakawa tsarin garkuwar jiki ya kai hari kansar, kuma yana iya tsoma baki tare da ikon ƙwayoyin ƙari don girma da yaɗuwa.
Wuri: Wurare 744
Nivolumab tare da ko ba tare da Ipilimumab a Kula da Marasa lafiya tare da Rashin Cancer Canal Canal
Wannan gwajin na biyu yana nazarin yadda nivolumab tare da ko ba tare da ipilimumab ke aiki ba wajen kula da marasa lafiya da cutar sankara ta dubura wacce ba ta amsa maganin da ya gabata ba (ƙin yarda) kuma ya bazu zuwa wasu wurare a cikin jiki (metastatic). Immunotherapy tare da kwayoyin cuta na monoclonal, irin su nivolumab da ipilimumab, na iya taimakawa tsarin garkuwar jiki ya kai hari kansar, kuma yana iya tsoma baki tare da ikon ƙwayoyin tumo don girma da yaɗuwa.
Wuri: wurare 42
Nivolumab da Ipilimumab wajen Kula da Marasa lafiya tare da HIV Associated Relapsed ko Refractory Classical Hodgkin Lymphoma ko Solid Tumors Wadanda suke Metastatic ko Ba'a Iya Cire Ta Tiyata
Wannan gwajin na lokaci yana nazarin illoli ne da mafi kyawun kwayar cutar nivolumab lokacin da aka bawa ipilimumab wajen kula da marasa lafiya tare da kwayar cutar kanjamau (HIV) mai alaƙa da hompkin lymphoma na yau da kullun wanda ya dawo bayan wani lokaci na ci gaba ko baya amsa magani, ko ciwan ciwace sun bazu zuwa wasu wurare a cikin jiki ko kuma ba za a iya cire su ta hanyar tiyata. Immunotherapy tare da kwayoyin cuta na monoclonal, kamar ipilimumab da nivolumab, na iya taimakawa tsarin garkuwar jiki ya kai hari kansar, kuma yana iya tsoma baki tare da ikon ƙwayoyin ƙwayoyin cuta su girma da yaɗuwa. Ipilimumab abu ne mai kare kansa wanda yake aiki akan kwayar halitta da ake kira cytotoxic T-lymphocyte antigen 4 (CTLA-4). CTLA-4 tana sarrafa wani sashi na tsarin garkuwar ku ta hanyar rufe shi. Nivolumab wani nau'in antibody ne wanda yake takamaimai ga rayuwar ɗan adam da aka tsara 1 (PD-1), furotin wanda ke da alhakin lalata ƙwayoyin cuta. Ba da ipilimumab tare da nivolumab na iya aiki mafi kyau wajen kula da marasa lafiya da ke haɗuwa da kwayar cutar HIV ta Hodgkin lymphoma na gargajiya ko ƙwayoyin cuta masu ƙarfi idan aka kwatanta da ipilimumab tare da nivolumab ita kaɗai.
Wuri: wurare 28
Nazarin XmAb®20717 a cikin Batutuwa Tare da Zaɓaɓɓun Twararrun umwayoyi
Wannan na 1 ne na zamani, kashi dayawa, yawan kara hauhawar bincike don bayyana MTD / RD da tsarin XmAb20717, don bayyana aminci da juriya, don tantance PK da rigakafin cuta, kuma don tantance aikin hana tumor na XmAb20717 a cikin batutuwa tare da zaɓaɓɓu ci gaba m marurai.
Wuri: Wurare 15
Nazarin Immuno-far Nazarin don Nazarin Tsaro da Ingancin Nivolumab, da Nivolumab Combination Farrapy a cikin ƙwayoyin cuta masu alaƙa da ƙwayoyin cuta
Dalilin wannan binciken don bincika aminci da tasirin nivolumab, da kuma maganin haɗin nivolumab, don magance marasa lafiya waɗanda ke da ƙwayoyin cuta masu alaƙa da ƙwayoyin cuta. An san wasu ƙwayoyin cuta suna taka rawa wajen samar da ƙari da girma. Wannan binciken zai binciki tasirin magungunan, a cikin marasa lafiyar da ke da nau'ikan ciwace ciwace ci gaba: - Canal na canal na canjin-Ba a sake yin rajista da wannan nau'in ciwon - Ciwon sankarar mahaifa - Epstein Barr Virus (EBV) tabbatacce kansar ciki - Ba a sake yin wannan nau'in ƙari - Ciwon ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta - Ciwon daji na Penile-Ba a sake yin rajistar irin wannan ciwon ba - Ciwon daji na mata da na mara - Ba a sake yin rajistar wannan nau'in ƙwayar cutar ba - Nasopharyngeal Cancer - Ba a sake yin rajistar wannan nau'in ciwon - Ciwon da Ciwon Cancer - Ba a sake yin rajistar wannan nau'in tumo ba
Wuri: wurare 10
Nazarin Pembrolizumab (MK-3475) a cikin Mahalarta Tare da Ciwon Tumurai Masu Inganci (MK-3475-158 / KEYNOTE-158)
A cikin wannan binciken, mahalarta tare da nau'o'in ci gaba masu yawa (waɗanda ba za a iya tantancewa ba da / ko kuma masu haɗari) waɗanda suka ci gaba a kan daidaitaccen maganin kulawa za a bi da su tare da pembrolizumab.
Wuri: Wurare 8
High-Dose-Rate Brachytherapy da Chemotherapy a Kula da Marasa lafiya tare da Maimaitawar Gida ko Ragowar orwararru ko Ciwon Cutar Canjin Canjin Rashin Gudanarwa
Wannan lokaci na gwaji na nazarin illolin illa da mafi kyawun kwayar maganin ƙoshin lafiya mai ƙarfi yayin da aka ba su tare da maganin ƙwaƙwalwa don kula da marasa lafiya da ciwon sankarar ƙugu ko na dubura wanda ya dawo ko ya daɗa muni kuma ba za a iya magance shi da tiyata ba. Brachytherapy, wanda aka fi sani da farfadowa na cikin gida, yana amfani da kayan aikin rediyo da aka sanya kai tsaye zuwa ko kusa da ƙari don kashe ƙwayoyin tumo. Braaramar-ƙimar-ƙarfin (HDR) brachytherapy tana amfani da kayan aikin rediyo don sadar da babban ƙwayar radiation cikin ƙanƙanin lokaci zuwa ƙari. Hakanan yana iya aika ƙaramin radiation zuwa ƙwayoyin lafiya masu kusa kuma yana iya rage haɗarin illa. Magungunan da ake amfani da su a jiyyar cutar sankara, kamar su capecitabine da fluorouracil, suna aiki ta hanyoyi daban-daban don dakatar da haɓakar ƙwayoyin tumo, ko dai ta hanyar kashe ƙwayoyin, ta hana su rarraba, ko kuma ta hana su yaɗuwa.
Wuri: Wurare 6
Pembrolizumab a Kula da Marasa lafiya tare da Ciwon Cutar Ciwon Cutar Metastatic ko Ciwon Cikin Gida wanda Ba Zai Iya Cire Ta Tiyata ba
Wannan gwajin na lokaci na II yana nazarin yadda pembrolizumab ke aiki sosai wajan kula da marasa lafiya masu cutar sankara wacce ta bazu zuwa wasu wurare a cikin jiki ko kuma ta yaɗu daga asalin shafin ta na ci gaba zuwa kayan da ke kusa ko ƙwayoyin lymph kuma ba za'a iya cire su ta hanyar tiyata ba. Immunotherapy tare da kwayoyin cuta na monoclonal, kamar pembrolizumab, na iya taimaka wa garkuwar jiki ta kai hari ga kansar, kuma yana iya tsoma baki tare da ikon ƙwayoyin ƙari don girma da yaɗuwa.
Wuri: Wurare 5
Yin tiyata a cikin Kula da Marasa lafiya tare da Canal Canal Canal ko Cancer na Perianal da HIV mai Kyau
Wannan gwajin gwaji na zamani ana yin aikin tiyata ne wajen kula da marasa lafiya da cutar ta dubura ko kuma cutar sankarau wacce karama ce kuma ba ta yadu sosai cikin kwayoyin halitta da kwayar cutar kanjamau (HIV) tabbatacciya. Yin aikin tiyata na gida na iya zama mafi aminci magani tare da ƙananan sakamako masu illa fiye da babbar tiyata ko radiation da chemotherapy.
Wuri: Wurare 5
Gwaji don Nemo da Bincike Tsarin Lafiya na Sabon Kayan (BI 754091) ga Marasa lafiya da Ciwon Tumurai
Babban mahimmancin ɓangaren haɓakar haɓakar gwaji shine don ƙayyade aminci da juriya, da kuma ƙayyade Toimar Maɗaukaki Mafi Girma da / ko Rewararren Kashi na 2 (RP2D) na BI 754091 bisa ga marasa lafiya tare da iyakancewar kashi guba (DLTs) a cikin marasa lafiya tare da zaɓaɓɓun ƙwayoyin cuta masu ƙarfi. Za a kimanta aminci da juriya ta hanyar lura da faruwar abubuwa masu banƙyama (AEs), manyan AEs (SAE), da mawuyacin yanayin sashin bincike, da canje-canje ga mahimman alamu. Manufofin sakandare shine ƙaddarar bayanin PK na BI 754091 bayan guda ɗaya da ɗimbin yawa na BI 754091, da kuma kimantawa na farko na aikin ɓarna. A cikin ɓangaren fadada sashi na gwaji, manyan manufofin sune don ƙara kimanta aminci, inganci, bayanin PK,
Wuri: Wurare 3
Stereotactic Radiosurgery a Kula da Marasa lafiya da Ciwon Oligometastatic
Wannan gwajin na lokaci na II yana nazarin yadda ingantaccen rediyo ke aiki wajen kula da marasa lafiya da cutar kansa wanda ya bazu zuwa 5 ko ƙananan wurare a jiki kuma ya ƙunshi 3 ko ƙananan gabobin (cutar oligometastatic). Yin aikin tiyata na stereotactic, wanda aka fi sani da farfado da ƙwayar cuta ta jiki, magani ne na musamman wanda ke ba da kashi ɗaya, madaidaiciyar jujjuyawar kai tsaye ga ƙari kuma yana iya kashe ƙarin ƙwayoyin ƙwayoyin cuta kuma ya haifar da raunin lalacewar kayan aiki na al'ada.
Wuri: Wurare 3
Nazarin INCMGA00012 a cikin Cutar Cancer na Canal Bayan Canjin Chetotherapy na Platinum (POD1UM-202)
Dalilin wannan binciken shine a tantance ingancin INCMGA00012 a cikin mahalarta tare da ci gaban cikin gida ko ƙananan ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta (SCAC) waɗanda suka ci gaba bayan sunadarai mai yaduwar platinum.
Wuri: Wurare 4
Artesunate a Kula da Marasa lafiya tare da Hanyar Intraepithelial Neoplasia
Wannan lokacin na gwaji na nazarin illolin illa da mafi kyawun maganin artesunate wajen kula da marasa lafiya tare da babban kwayar cutar cikin inzali na neoplasia. Anop intraepithelial neoplasia ƙananan ƙwayoyin cuta ne waɗanda ƙila ba za su iya zama cutar kansa a nan gaba ba. Yawancin sauye-sauyen da ke haifar da cutar kansa suna faruwa ne daga papillomavirus ta mutum (HPV). Artesunate na iya kashe ƙwayoyin da ke kamuwa da HPV.
Wuri: Wurare 2
Nazarin LY3434172, PD-1 da PD-L1 Bishop na Musamman, a Ciwon Ciwon Cutar
Babban manufar wannan binciken shine a kimanta aminci da jure maganin binciken LY3434172, PD-1 / PD-L1 bispecific antibody, a cikin mahalarta tare da ciwace ciwace mai ƙarfi.
Wuri: Cibiyar Cancer ta MD Anderson, Houston, Texas
SL-279252 (PD1-Fc-OX40L) a cikin Batutuwa Tare da Ci gaba Mai Ciwan Tumur ko Lymphomas
Wannan shi ne farkon 1 na farko a cikin ɗan adam, buɗaɗɗen lakabi, cibiyoyi da yawa, haɓaka ci gaba da nazarin fadada kashi don kimanta aminci, haƙuri, PK, aikin rigakafin tumor da tasirin pharmacodynamic na SL-279252 a cikin batutuwa da ke da ciwan ciwan ci gaba ko ƙwayoyin cuta. .
Wuri: Cibiyar Cancer ta MD Anderson, Houston, Texas
LET-IMPT da Daidaitaccen Chemotherapy a Kula da Marasa lafiya tare da Sabon Gano Hannun I-III
Wannan gwajin na zamani na biyu yana nazarin illolin LET-IMPT da daidaitaccen ilimin kimiya, da yadda suke aiki yadda ya kamata wajen kula da marasa lafiya tare da sabon gwajin cutar I-III mai saurin cutar sankara. LET-IMPT wani nau'in maganin fure ne wanda yake amfani da proton proton “beamlets” don “fentin” sinadarin radiation a cikin niyya kuma yana iya taimakawa wajen kashe kwayoyin cuta da rage jijiyoyin. Bayar da LET-IMPT da daidaitaccen ilimin kimiya na iya aiki mafi kyau wajen kula da marasa lafiya tare da cutar sankara da kewaya ta sankara.
Wuri: Cibiyar Cancer ta MD Anderson, Houston, Texas
VGX-3100 da Electroporation a Kula da Marasa lafiya tare da Cutar HIV mai Inganci
Wannan matakin na II yana nazarin yadda kwayar cutar papillomavirus (HPV) ta deoxyribonucleic acid (DNA) ta keɓaɓɓiyar rigakafin magani ta VGX-3100 (VGX-3100) da kuma aikin samar da wutan lantarki wajen kula da marasa lafiya da ke fama da kwayar cutar kanjamau (HIV). Alurar rigakafin da aka yi daga DNA na iya taimakawa jiki gina ingantaccen maganin rigakafi don kashe ƙwayoyin tumo. Lantarki yana taimakawa pores a cikin kwayoyin jikin ku shan magani don karfafa garkuwar jikin ku. Bayar da VGX-3100 tare da yin amfani da wutar lantarki tare na iya aiki mafi kyau wajen kula da marasa lafiya da cututtukan fulawa masu girma.
Wuri: Wurare 2
DNA Plasmid-encoding Interleukin-12 / HPV DNA Plasmids Allurar rigakafi INO-3112 da Durvalumab a Kula da Marasa lafiya tare da Maimaitawa ko Metastatic Human Papillomavirus Associated Cancers
Wannan gwajin na lokaci na biyu yana nazarin yadda deoxyribonucleic acid (DNA) da ke sanya kwayar cutar interleukin-12 / human papillomavirus (HPV) DNA plasmids maganin warkewa INO-3112 da aikin durvalumab wajen kula da marasa lafiya da cututtukan papillomavirus masu alaƙa da suka dawo ko yaɗuwa zuwa wasu wurare a cikin jiki. Allurar rigakafin da aka yi daga kwayar da aka canza ta kwayar halitta na iya taimakawa jiki gina ingantaccen maganin rigakafi don kashe ƙwayoyin tumo. Immunotherapy tare da kwayoyin cuta na monoclonal, irin su durvalumab, na iya taimakawa tsarin garkuwar jiki ya kai hari kansar, kuma yana iya tsoma baki tare da ikon ƙwayoyin ƙari don girma da yaɗuwa. Bayar da ƙwayar plasmid-encoding interleukin-12 / HPV DNA plasmids maganin warkewa INO-3112 da durvalumab na iya aiki mafi kyau wajen kula da marasa lafiya da cututtukan papillomavirus masu alaƙa da mutum.
Wuri: Cibiyar Cancer ta MD Anderson, Houston, Texas
M7824 a cikin Batutuwa Tare da HPV Associated Malignancies
Bayan Fage: A Amurka, a kowace shekara akwai fiye da cututtukan 30,000 na cututtukan papillomavirus (HPV) masu alaƙa da cutar kansa. Wasu daga cikin waɗannan cututtukan ba su da magani kuma ba a inganta su ta hanyar hanyoyin kwantar da hankali. Masu bincike suna so su ga ko wani sabon magani M7824, wanda ke niyya da toshe hanyar da ke hana tsarin rigakafi daga yaƙar kansa da kyau zai iya rage ƙwayar cuta a cikin mutanen da ke da wasu cututtukan HPV. Manufofin: Don ganin idan maganin M7824 na haifar da ciwace-ciwace. Cancanta: Manya daga shekara 18 zuwa sama waɗanda ke da cutar kansa wanda ke da alaƙa da kamuwa da cutar ta HPV. Zane: Za a bincika masu shiga tare da tarihin likita da gwajin jiki. Zasu sake nazarin alamun su da kuma yadda suke gudanar da ayyukan su na yau da kullun. Za su yi sikanin jiki. Zasu bada jini da fitsari. Za'a ɗauki samfurin ƙwayoyin jikinsu na tumor idan ba'a samu ba. Mahalarta zasuyi amfani da lantarki don kimanta zuciyarsu. Sannan zasu sami maganin karatun ta wani bakin bututu a jijiyar hannu. Mahalarta zasu sami maganin a kowane sati 2 na lokutan 26 (shekara 1). Wannan hanya 1 ce. Bayan kwas ɗin, za a sa ido kan mahalarta amma ba za su sha magungunan karatun ba. Idan yanayin su yayi tsanani, zasu fara wata hanya tare da maganin. Wannan aikin za'a iya maimaita shi sau da yawa kamar yadda ake buƙata. Jiyya zai daina idan ɗan takarar yana da mummunan sakamako ko magani ya daina aiki. Duk lokacin nazarin, mahalarta zasu sake maimaita wasu ko duk gwajin gwajin. Bayan mahalarta sun daina shan ƙwaya, za su sami ziyarar bibiyar kuma su maimaita wasu gwaje-gwaje na gwaji. Za su sami kiran waya na lokaci-lokaci. ... Sannan zasu sami maganin karatun ta wani bakin bututu a jijiyar hannu. Mahalarta zasu sami maganin a kowane sati 2 na lokutan 26 (shekara 1). Wannan hanya 1 ce. Bayan kwas ɗin, za a sa ido kan mahalarta amma ba za su sha magungunan karatun ba. Idan yanayin su yayi tsanani, zasu fara wata hanya tare da maganin. Wannan aikin za'a iya maimaita shi sau da yawa kamar yadda ake buƙata. Jiyya zai daina idan ɗan takarar yana da mummunan sakamako ko magani ya daina aiki. Duk lokacin nazarin, mahalarta zasu sake maimaita wasu ko duk gwajin gwajin. Bayan mahalarta sun daina shan ƙwaya, za su sami ziyarar bibiyar kuma su maimaita wasu gwaje-gwaje na gwaji. Za su sami kiran waya na lokaci-lokaci. ... Sannan zasu sami maganin karatun ta wani bakin bututu a jijiyar hannu. Mahalarta zasu sami maganin a kowane sati 2 na lokutan 26 (shekara 1). Wannan hanya 1 ce. Bayan kwas ɗin, za a sa ido kan mahalarta amma ba za su sha magungunan karatun ba. Idan yanayin su yayi tsanani, zasu fara wata hanya tare da maganin. Wannan aikin za'a iya maimaita shi sau da yawa kamar yadda ake buƙata. Jiyya zai daina idan ɗan takarar yana da mummunan sakamako ko magani ya daina aiki. Duk lokacin nazarin, mahalarta zasu sake maimaita wasu ko duk gwajin gwajin. Bayan mahalarta sun daina shan ƙwaya, za su sami ziyarar bibiyar kuma su maimaita wasu gwaje-gwaje na gwaji. Za su sami kiran waya na lokaci-lokaci. ... za a sa ido kan mahalarta amma ba za su sha maganin shan magani ba. Idan yanayin su yayi tsanani, zasu fara wata hanya tare da maganin. Wannan aikin za'a iya maimaita shi sau da yawa kamar yadda ake buƙata. Jiyya zai daina idan ɗan takarar yana da mummunan sakamako ko magani ya daina aiki. Duk lokacin nazarin, mahalarta zasu sake maimaita wasu ko duk gwajin gwajin. Bayan mahalarta sun daina shan ƙwaya, za su sami ziyarar bibiyar kuma su maimaita wasu gwaje-gwaje na gwaji. Za su sami kiran waya na lokaci-lokaci. ... mahalarta za a sa musu ido amma ba za su sha maganin karatun ba. Idan yanayin su yayi tsanani, zasu fara wata hanya tare da maganin. Wannan aikin za'a iya maimaita shi sau da yawa kamar yadda ake buƙata. Jiyya zai daina idan ɗan takarar yana da mummunan sakamako ko magani ya daina aiki. Duk lokacin nazarin, mahalarta zasu sake maimaita wasu ko duk gwajin gwajin. Bayan mahalarta sun daina shan ƙwaya, za su sami ziyarar bibiyar kuma su maimaita wasu gwaje-gwaje na gwaji. Za su sami kiran waya na lokaci-lokaci. ... Bayan mahalarta sun daina shan ƙwaya, za su sami ziyarar bibiyar kuma su maimaita wasu gwaje-gwaje na gwaji. Za su sami kiran waya na lokaci-lokaci. ... Bayan mahalarta sun daina shan ƙwaya, za su sami ziyarar bibiyar kuma su maimaita wasu gwaje-gwaje na gwaji. Za su sami kiran waya na lokaci-lokaci. ...
Wuri: Cibiyoyin Kula da Kiwon Lafiya na Nationalasa, Bethesda, Maryland
MnSOD Mimetic BMX-001 a Kula da Marasa Lafiya tare da Ciwon Cancer na Cancer na Radiation Far da Chemotherapy
Wannan lokaci na gwaji na nazarin mafi kyawun sashi na MnSOD mimetic BMX-001 don rage sakamako masu illa a cikin marasa lafiya da ke fama da cutar sankarar tsakar ciki wanda ke shan magani na radiation da kuma cutar sankara. Magungunan kare lafiyar jiki, kamar su BMX-001, na iya kare ƙwayoyin halitta na yau da kullun daga sakamakon illa na chemotherapy yayin haɓaka haɓakar ƙari.
Wuri: Jami'ar Cibiyar Kiwon Lafiya ta Nebraska, Omaha, Nebraska
Atezolizumab da Bevacizumab a Kula da Marasa lafiya tare da umananan Tumor
Wannan gwajin na lokaci na II yana nazarin yadda atezolizumab da bevacizumab ke aiki da kyau wajen kula da marasa lafiya da ƙananan ƙwayoyi. Immunotherapy tare da kwayoyin cuta na monoclonal, kamar atezolizumab da bevacizumab, na iya taimaka wa garkuwar jiki ta kai hari kan kansa, kuma yana iya tsoma baki tare da ikon ƙwayoyin ƙwayoyin cuta su girma da yaɗuwa.
Wuri: Cibiyar Cancer ta MD Anderson, Houston, Texas
Magungunan rigakafi da Cyclophosphamide a Kula da Marasa lafiya tare da HLA-A * 02 Tabbatacce Ya Rushe, laarfafawa, ko Metastatic HPV16 Mai Rarraba Oropharyngeal, Cervical, ko Anal Cancer
Wannan lokacin gwajin Ib / II yana nazarin illoli da mafi kyawun kwayar HPV16-E711-19 nanomer rigakafin DPX-E7 da kuma ganin yadda yake aiki idan aka bashi tare da cyclophosphamide wajen kula da marasa lafiya da HLA-A * 02 tabbatacce, ɗan adam papillomavirus 16 ( HPV16) - wanda ke da alaƙa da cutar sankarar mahaifa, na mahaifa, ko na dubura wanda ya dawo, ba ya karɓar magani, ko ya bazu zuwa wasu sassan jiki. Allurar rigakafin da aka yi daga kwayar da aka canza ta kwayar halitta na iya taimakawa jiki gina ingantaccen maganin rigakafi don kashe ƙwayoyin tumo. Magungunan da ake amfani da su a jiyyar cutar sankara, kamar su cyclophosphamide, suna aiki ta hanyoyi daban-daban don dakatar da haɓakar ƙwayoyin tumo, ko dai ta hanyar kashe ƙwayoyin, ta hana su rarraba, ko ta hana su yaɗuwa. Bayar da HPV16-E711-19 nanomer alurar rigakafin DPX-E7 tare da cyclophosphamide na iya aiki mafi kyau wajen kula da marasa lafiya da cutar ta HPV16 mai lafazin oropharyngeal,
Wuri: Dana-Farber Cibiyar Cancer, Boston, Massachusetts
Nivolumab da Ipilimumab a Kula da Marasa lafiya da Ciwan Tumuwa
Wannan karatuttukan gwaji na lokaci na biyu nivolumab da ipilimumab wajen kula da marasa lafiya da ƙananan ƙwayoyi. Immunotherapy tare da kwayoyin cuta na monoclonal, irin su nivolumab da ipilimumab, na iya taimakawa tsarin garkuwar jiki ya kai hari kansar, kuma yana iya tsoma baki tare da ikon ƙwayoyin tumo don girma da yaɗuwa. Wannan gwajin ya sanya mahalarta don masu haɗin gwiwa masu zuwa bisa ga yanayin: 1. Cutar tumɓir na ƙoshin hanci, sinuses, nasopharynx: A) Ciwon ƙwayar ƙwayar ƙwayar ƙwayar cuta tare da nau'ikan ramin hanci, sinuses, da nasopharynx da trachea (ban da laryngeal, nasopharyngeal cancer [NPC] , da kwayar cutar kankara da ke kan mutum da wuya [SCCHN]) B) Adenocarcinoma da bambance-bambancen jijiyar hanci, sinuses, da nasopharynx (rufe zuwa taruwa 07/27/2018) 2. Cutar tumfafir na manyan gland na jijiyoyin jiki (rufe don taruwa 03 / 20/2018) 3. Nauyin gland na salivary na ciwan kai da wuya, lebe, esophagus, ciki, trachea da huhu, nono da sauran wurare (rufe don tarawa) 4. Carcinoma da ba a rarrabe a cikin hanji na hanji (GI) 5. Adenocarcinoma tare da bambance-bambancen ƙananan hanji (an rufe don tarawa) 05/10/2018) 6. Kwayar cututtukan ƙwayoyin ƙwayoyin ƙwayoyin cuta tare da nau'ikan GI tract (ƙananan hanji, hanji, dubura, ƙuƙwarar)) (an rufe shi zuwa ƙara 10/17/2018) 7. Fibromixoma da adenocarcinoma mai ƙananan mucinous (pseudomixoma peritonei) na appendix da ovary (an rufe su don tarawa 03/20/2018) 8. Rare pancreatic ciwan ciki har da acinar cell carcinoma, mucinous cystadenocarcinoma ko serous cystadenocarcinoma. Pancreatic adenocarcinoma bai cancanci 9. Intrahepatic cholangiocarcinoma (an rufe shi don tarawa 03/20/2018) 10. Extrahepatic cholangiocarcinoma da bile duct marurai (an rufe su don tarawa 03/20/2018) 11. Sarcomatoid carcinoma na huhu 12. Bronchoalveolar carcinoma lung. Wannan yanayin da aka yanzu ma ake magana a kai a matsayin adenocarcinoma a wuri, minimally cin zali adenocarcinoma, lepidic m adenocarcinoma, ko cin zali mucinous adenocarcinoma 13. Non-epithelial marurai na kwai: A) jam cell ƙari na kwai B) Mullerian gauraye da ƙari kuma adenosarcoma (rufaffiyar zuwa tara 03/30/2018) 14. Trophoblastic tumor: A) Choriocarcinoma (an rufe shi zuwa tara 04/15/2019) 15. Cancin ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta ba tare da na koda ba, ƙashin ƙugu, ureter, ko mafitsara (an rufe shi don tara 04 / 15/2019) 16. Ciwon ƙwayar ƙwayar ƙwayar ƙwayar cuta da ƙari na ƙwayar cuta: Magungunan Apocrine / extramammary Paget's cuta 40. Peritoneal mesothelioma 41. Basal cell carcinoma 42. Bayyanar sankarar mahaifa 43. Esthenioneuroblastoma 44. Ecinetrial carcinosarcoma (mugayen cakuda cututtukan Mullerian) (an rufe su don tarawa) 45. Kwayar salula mai bayyana mahaifa cutar sankarar jakar kwai 47. Cutar cututtukan ciki na gestational (GTD) 48. Cutar kansar gallbladder 49. Smallaramin ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwai, nau'in hypercalcemic na 50. PD-L1 da aka haɓaka ƙari 51. Angiosarcoma 52. Ciwan ƙwayar neuroendocrine mai girma (ciwon ƙwayar neuroendocrine na pancreatic [PNET] ya kamata a sanya su a cikin Cohort 22; ya kamata a shigar da carcinomas na prostate neuroendocrine a cikin Cohort 53). Aramar ƙwayar ƙwayar huhu ba ta cancanci 53 ba. Ciwon ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta ta jiki (t-SCNC) Bayyanannen sankarar mahaifa 43. Esthenioneuroblastoma 44. Endometrial carcinosarcoma (mummunan haɗarin ƙwayoyin Mullerian) (an rufe su don tarawa) 45. Bayyanar sankarar mahaifa na mahaifa 46. Cutar sankarar mahaifa ta mata 47. Gastational trophoblastic disease (GTD) 48. Gallbladder cancer 49. Small carcinoma na kwayayen, nau'in hypercalcemic iri 50. PD-L1 kara girma ciwace ciwan 51. Angiosarcoma 52. Babban ciwon neuroendocrine carcinoma (pancreatic neuroendocrine tumo [PNET] ya kamata a shiga cikin Cohort 22; prostatic neuroendocrine carcinomas ya kamata a shiga cikin Cohort 53). Aramar ƙwayar ƙwayar huhu ba ta cancanci 53 ba. Ciwon ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta ta jiki (t-SCNC) Bayyanannen sankarar mahaifa 43. Esthenioneuroblastoma 44. Endometrial carcinosarcoma (mummunan haɗarin ƙwayoyin Mullerian) (an rufe su don tarawa) 45. Bayyanar sankarar mahaifa na mahaifa 46. Cutar sankarar mahaifa ta mata 47. Gastational trophoblastic disease (GTD) 48. Gallbladder cancer 49. Small carcinoma na kwayayen, nau'in hypercalcemic iri 50. PD-L1 kara girma ciwace ciwan 51. Angiosarcoma 52. Babban ciwon neuroendocrine carcinoma (pancreatic neuroendocrine tumo [PNET] ya kamata a shiga cikin Cohort 22; prostatic neuroendocrine carcinomas ya kamata a shiga cikin Cohort 53). Aramar ƙwayar ƙwayar huhu ba ta cancanci 53 ba. Ciwon ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta ta jiki (t-SCNC) Clear cell ovarian cancer 47. Ciwon kwankwasar ciki na ciki (GTD) 48. Gallbladder cancer 49. Smallananan ƙwayoyin ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta, nau'in 50 na hypercalcemic 50. PD-L1 da aka haɓaka ƙari 51. Angiosarcoma 52. Ciwon ƙananan neuroendocrine carcinoma (ciwon daji na neuroendocrine tumor [PNET ] ya kamata a sanya hannu a cikin Cohort 22; ya kamata a shigar da carcinomas neuroendocrine na prostatic a cikin Cohort 53). Aramar ƙwayar ƙwayar huhu ba ta cancanci 53 ba. Ciwon ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta ta jiki (t-SCNC) Clear cell ovarian cancer 47. Ciwon kwankwasar ciki na ciki (GTD) 48. Gallbladder cancer 49. Smallananan ƙwayoyin ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta, nau'in 50 na hypercalcemic 50. PD-L1 da aka haɓaka ƙari 51. Angiosarcoma 52. Ciwon ƙananan neuroendocrine carcinoma (ciwon daji na neuroendocrine tumor [PNET ] ya kamata a sanya hannu a cikin Cohort 22; ya kamata a shigar da carcinomas neuroendocrine na prostatic a cikin Cohort 53). Aramar ƙwayar ƙwayar huhu ba ta cancanci 53 ba. Ciwon ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta ta jiki (t-SCNC) ya kamata a shigar da carcinomas neuroendocrine na prostatic a cikin Cohort 53). Aramar ƙwayar ƙwayar huhu ba ta cancanci 53 ba. Ciwon ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta ta jiki (t-SCNC) ya kamata a shigar da carcinomas neuroendocrine na prostatic a cikin Cohort 53). Aramar ƙwayar ƙwayar huhu ba ta cancanci 53 ba. Ciwon ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta ta jiki (t-SCNC)
Wuri: wurare 878
